VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

BSH 2022 | Updates from the HD21 study: escalated BEACOPP vs BrECADD for the treatment of HL

In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the HD21 trial (NCT02661503), a highly anticipated clinical trial comparing the use of escalated BEACOPP with BrECADD in patients with classical Hodgkin lymphoma (HL). Dr Collins first discusses the differences between the BEACOPP and BrECADD protocols, and further explains the main aim of this study, which is to investigate whether BrECADD is less toxic than the commonly used escalated BEACOPP approach. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.


Honoraria: Roche, Takeda, Gilead, Pfizer, MSD, Celleron, ADC Therapeutics, Incyte, Beigene. Research funding: BMS, MSD, Celleron, Amgen, BMS

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter